The Global Peptide Market Will Exceed $60 Billion by 2030
1 min read
The therapeutic peptide market is booming. According to Grand View Research analysts, it is expected to grow from $42 billion in 2024 to over $60 billion by 2030.
Several factors explain this growth:
ADVANTAGES OF PEPTIDES
- High specificity: fewer side effects than small molecules
- Biodegradability: no accumulation in the body
- Modular synthesis: sequence customization possible
- Tolerance: generally favorable safety profile
KEY FIGURES
- 80+ peptides approved by the FDA
- 150+ peptides in clinical trials
- 7 of the 10 best-selling drugs in 2024 are biologics
GROWING AREAS
- Metabolism: GLP-1 agonists (Ozempic, Mounjaro)
- Oncology: peptides targeting tumor receptors
- Rare diseases: orphan peptide therapies
- Cosmetics: anti-aging peptides and skin repair
Major laboratories (Novo Nordisk, Eli Lilly, Amgen, Ipsen) are investing heavily in peptide R&D. Innovation is particularly focused on improving oral bioavailability, long considered the Holy Grail of the sector.
